Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind…
By G. Agnelli, G. Gussoni, C. Bianchini, M. Verso, M. Mandalà, L. Cavanna, S. Barni, R. Labianca, F. Buzzi, G. Scambia and 6 more. The Lancet Oncology, 2009
599 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Oncology
View Paper: https://www.semanticscholar.org/paper/cd76b71fac2768dcd94f595291af541f1e85881c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
Citations in the corpus
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, methodology): “Of the 17 eligible RCTs, we included 12 RCTs for which we had access to their individual participant data in the meta-analysis.(223-225,228-234,237,238) One study used UFH as the intervention,(229) and another used ultra-LMWH(223); the rest used LMWH.”
- Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations—2019 update (2019, background): “85 86 The recently published randomized, placebo-controlled AVERT trial of prophylactic apixaban during solid tumor chemotherapy demonstrated a 60% reduction in VTE in those randomized to apixaban.”
- Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013, methodology): “The primary end point for PROTECHT was a composite of symptomatic VTEs and arterial thromboembolic events during treatment and follow-up.(19) In PROTECHT, 3.”